Physician profile
Bachar Dahman
NPI 1528006566
$1,090.50
in general payments reported to CMS, 2019-2025
13 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.29 · 2020: $108 · 2022: $14.62 · 2023: $120 · 2024: $397 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.41 | 2019-2025 | Linzess, Viberzi |
| Boston Scientific Corporation | $161.83 | 2019-2024 | Autotome Rx 49 |
| Janssen Biotech, INC. | $131.02 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $91.71 | 2019-2024 | Ocaliva |
| Lilly USA, LLC | $64.88 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $57.70 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $43.90 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $42.86 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $35.75 | 2024 | Voquezna |
| Alnylam Pharmaceuticals INC. | $25.09 | 2024 | Givlaari |
| Ardelyx, INC. | $22.40 | 2025 | Ibsrela |
| Novo Nordisk INC | $15.33 | 2025 | Wegovy |
| Medtronic, INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Dahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.